Literature DB >> 10687859

Effect of PRL on MAPK activation: negative regulatory role of the C-terminal part of the PRL receptor.

O Goupille1, J V Barnier, B Guibert, J Paly, J Djiane.   

Abstract

Prolactin induces cell proliferation and cell differentiation through well-known MAPK Erk, and JAK2/STAT5 pathways depending on the cell line. The aim of the present study was to delineate the functional domains of the PRL receptor involved in PRL induced MAPK regulation. Using various PRL-R mutants of the cytoplasmic domain we found, that the membrane proximal domain is necessary for PRL induced MAPK activation and that the C-terminal part of the receptor exerts a negative regulatory role. A pharmacological approach, using different types of inhibitors, provided evidence that PRL induced MAPK activation requires both a MEK dependent pathway and a PI3K dependent pathway. The negative regulation induced by the carboxy-terminal part of the receptor involves a combination of tyrosine phosphatases and serine/threonine phosphatases as concluded from the actions of the phosphatase inhibitors: pervanadate, PAO and okadaic acid. The mechanism by which these phosphatases are recruited or are induced by the last 141 cytoplasmic residues of the receptor remains to be determined. Finally the negative regulatory role of the carboxy-terminal part of the receptor, first demonstrated in the present study, is discussed in terms of the regulation of different effects of PRL on growth and differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10687859     DOI: 10.1016/s0303-7207(99)00197-5

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  9 in total

Review 1.  Bridging the gap between GPCR activation and behaviour: oxytocin and prolactin signalling in the hypothalamus.

Authors:  Erwin H van den Burg; Inga D Neumann
Journal:  J Mol Neurosci       Date:  2010-09-24       Impact factor: 3.444

2.  Endogenous prolactin generated during peripheral inflammation contributes to thermal hyperalgesia.

Authors:  Phoebe E Scotland; Mayur Patil; Sergei Belugin; Michael A Henry; Vincent Goffin; Kenneth M Hargreaves; Armen N Akopian
Journal:  Eur J Neurosci       Date:  2011-07-21       Impact factor: 3.386

Review 3.  Breast Cancer and Prolactin - New Mechanisms and Models.

Authors:  Charles V Clevenger; Hallgeir Rui
Journal:  Endocrinology       Date:  2022-10-01       Impact factor: 5.051

4.  PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium.

Authors:  Joëlle Dupont; Jean Pierre Renou; Moshe Shani; Lothar Hennighausen; Derek LeRoith
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

Review 5.  Prolactin regulation of mammary gland development.

Authors:  Samantha R Oakes; Renee L Rogers; Matthew J Naylor; Christopher J Ormandy
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-25       Impact factor: 2.673

6.  Prolactin (PRL)-stimulated ubiquitination of ZnT2 mediates a transient increase in zinc secretion followed by ZnT2 degradation in mammary epithelial cells.

Authors:  Young Ah Seo; Sooyeon Lee; Stephen R Hennigar; Shannon L Kelleher
Journal:  J Biol Chem       Date:  2014-07-11       Impact factor: 5.157

7.  Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells.

Authors:  Feng Fang; Michael A Rycyzyn; Charles V Clevenger
Journal:  Endocrinology       Date:  2008-11-26       Impact factor: 4.736

8.  Prolactin activates mitogen-activated protein kinase signaling and corticotropin releasing hormone transcription in rat hypothalamic neurons.

Authors:  Annegret Blume; Luz Torner; Ying Liu; Sivan Subburaju; Greti Aguilera; Inga D Neumann
Journal:  Endocrinology       Date:  2008-11-20       Impact factor: 4.736

9.  Medicinal Mushroom Leucocalocybe mongolica Imai Extracts Improve Mammary Gland Differentiation in Lactating Rats via Regulating Protein Expression.

Authors:  Asmaa Hussein Zaki; Bao Haiying; Li Zhijun
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-18       Impact factor: 2.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.